Approximately 30–40% of all ER+ breast tumors exhibit an activating mutation of PIK3CA, which can either increase the catalytic activity or cause the retention of the p110α subunit, thereby promoting excessive cell multiplication and resistance to apoptosis [22,23]. This evidence concerns the gene PIK3CA and breast neoplasm.